Breaking News

OnCusp’s CUSP06 Receives FDA Fast Track Designation

CUSP06 is being evaluated in a Phase 1 study in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

Author Image

By: Charlie Sternberg

Associate Editor

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CUSP06, a Cadherin-6 targeting Antibody-Drug Conjugate (CDH6 ADC) and OnCusp Therapeutics Inc.’s lead program, for the treatment of patients with platinum-resistant ovarian cancer (PROC). “We are extremely pleased that the FDA granted Fast Track Designation to CUSP06,” said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. “The early results from our Phase 1 trial have...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters